7 citations
,
July 2007 in “Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy” The medication lopinavir-ritonavir may cause severe hair loss.
5 citations
,
July 2007 in “PubMed” An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
51 citations
,
August 2021 in “Turkish Journal of Medical Sciences” As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
1 citations
,
September 2022 in “Sudan Journal of Medical Sciences” Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
1 citations
,
November 2011 in “Journal of AIDS & Clinical Research” Raltegravir may cause hair loss in some patients.
17 citations
,
August 2002 in “AIDS” Indinavir and ritonavir therapy can cause reversible hair loss.
38 citations
,
August 1999 in “New England journal of medicine/The New England journal of medicine” Indinavir can cause hair loss and other skin problems.
6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” Golvatinib shows promise as a treatment for Omicron in elderly patients.
113 citations
,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
101 citations
,
July 2020 in “Dermatologic therapy” COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
84 citations
,
March 2010 in “Infectious Disease Clinics of North America” The document concludes that rapid identification, isolation, and strict infection control are crucial to manage SARS outbreaks.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
59 citations
,
October 2020 in “Stem Cell Reviews and Reports” Men have higher COVID-19 mortality rates than women due to biological and lifestyle factors.
51 citations
,
November 2020 in “Journal of the European Academy of Dermatology and Venereology” COVID-19 infection may cause significant hair loss, but full hair recovery is likely without special treatment.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
42 citations
,
November 2004 in “Paediatric Respiratory Reviews” Children generally have milder SARS symptoms than adults, with good outcomes and no deaths reported, but long-term effects are unclear.
36 citations
,
August 2021 in “Nature Cell Biology” Organoids can help study COVID-19 and develop treatments, but face challenges like instability and limited renewal.
35 citations
,
November 2020 in “Dermatologic Therapy” Severe COVID-19 may cause hair loss, and doctors recommend supplements and topical treatments to manage it.
34 citations
,
September 2020 in “BMC Endocrine Disorders” Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
31 citations
,
August 2020 in “EClinicalMedicine” Male cancer patients have a higher risk of severe illness and death from COVID-19 than female patients.
31 citations
,
June 2020 in “Dermatologic Therapy” Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.
25 citations
,
July 2021 in “Journal of Medical Virology” COVID-19 can cause various skin issues, including rashes and hair loss, which usually heal on their own and don't always indicate severe illness.
20 citations
,
September 2020 in “Journal of Translational Medicine” Mesenchymal stromal cells may help treat severe COVID-19, but more research is needed to confirm their effectiveness.
16 citations
,
June 2017 in “PLoS ONE” A 6-group hair classification is more reliable for drug testing than an 8-group system.
15 citations
,
August 2021 in “Reviews in endocrine and metabolic disorders” COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.
15 citations
,
December 2020 in “Pharmacology Research & Perspectives” Blocking enzymes that help the virus enter cells could be a promising way to treat COVID-19.
13 citations
,
October 2021 in “The Journal of Microbiology” Human placenta hydrolysate may help treat COVID-19 by reducing virus replication and boosting immune response.
12 citations
,
November 2022 in “Archives of Dermatological Research” COVID-19 can directly trigger certain skin conditions like pustular dermatoses due to an inflammatory response.
10 citations
,
January 2023 in “Molecular and Cellular Biochemistry” Solanum nigrum shows promise for treating COVID-19 and its complications, but more research is needed.